2nd Annual Cell-Based Assays Optimising methods and integrating new platforms for drug discovery, development and toxicity testing 11th – 13th October 2011, Visiongain Conference Centre, London, UK BOOK NOW! Key Speakers Julie Holder, Preclinical Director, Stem Cell DPU, GlaxoSmithKline Stefan Otto Mueller, Director, Early, Genetic and Molecular Toxicology, Merck Serono Rachel Russell, Director, Primary Pharmacology Group, Pfizer Darren Cawkill, Associate Director, Primary Pharmacology Group, Pfizer Miroslav Cik, Research Fellow, Janssen Pharmaceutica (Johnson & Johnson) Joanne Bowes, Principal Scientist, AstraZeneca Magalie Rocheville, Investigator, GlaxoSmithKline Stephen Minger, Global Head of R&D, Cellular Technologies, GE Healthcare Frank W. Bonner, Chief Executive, Stem Cells for Safer Medicines Mark Slack, Group Leader, Cellular Assays, Evotec Jasmin Fisher, Researcher, Executable Biology, Microsoft Research Cambridge Molly Stevens, Professor of Biomedical Materials and Regenerative Medicine, Imperial College London David C. Hay, Principal Investigator, MRC Centre for Regenerative Medicine, University of Edinburgh Stefan Przyborski, Founder and Chief Scientific Officer, Reinnervate Pre-conference Workshop, Tuesday 11th October, 2011 Industrial application of pluripotent stem cells and their derivatives- High-content screening as a valuable tool for drug discovery and toxicity testing Led by: Mikael Englund, Senior Scientist, Site Manager, Cellartis, Daniella Steel, Senior Scientist, Project Leader, Cellartis, Paul Andrews, Senior Scientist, Drug Discovery Unit, University of Dundee Panellists: Petter Björquist, Senior Principal Scientist, Project Manager, Cellartis, Anders Aspegren, Senior Scientist, Production Manager, CellartisAssociate Sponsor P H O T O N I S O U R B U S I N E S S Organised By Driving the Industry Forward | www.futurepharmaus.comMedia Partners To Book Call: +44 (0) 20 7336 6100 | www.visiongain.com/cell-based-assays
Conference Introduction 2nd Annual Cell-Based Assays 11th - 13th October 2011, London, UKDear Colleague, Associate Sponsor: t takes well over £500 million and between 10 and 12 years to develop a new drug. I InvivoSciences LLC is a frontier in developing next generation 3D cell For every million compounds screened, approximately 250 make it to pre-clinical culture and assay systems, providing unprecedented solutions for testing, 10 advance to clinical trials and just one is approved for patient use. Industry biomedical research, cosmetics, discovery, and toxicology screening. Two- can ill-afford to continue such a wasteful process. dimensional cell cultures used during early phase research do not reflect ancerous and animal cells, many having been in continuous culture for decades, C the real, internal, 3D environment, and falsely indicate potential results poorly reflect patient physiology. These, finally, are yielding to more representative from animal studies. Application of our products, a high-throughput screening device (Palpator ) and plastic consumables for 3D cell culture systems, can TM models that better reflect the intended recipients of new molecular entities. Advances in label-free technologies, human primary, 3D and embryonic-stem cell narrow this gap. The system precisely, rapidly, and cost-effectively quantifies the effects derived lines are heralding a paradigm shift in drug discovery, development and of drug candidates, chemicals, and gene products on the physiological properties of toxicity testing. reconstituted tissues (3D cell cultures), better reflecting in vivo tissue/organ functions. ocussing on these, the future tools that better reflect PK/PD, genomic and F For further information please visit: www.invivosciences.com phenotypic differences within and between human populations, Visiongain brings Lonza is one of the world’s leading suppliers to the pharmaceutical, you its second Cell-Based Assays conference. healthcare and life science industries. Lonza’s Bioscience Division Attending this event will empower you to: provides innovative, reliable products and services for drug discoverycell biology and molecular biology research and preclinical screening. We focus on primary cell • Utilise new techniques in high throughput screening. supply, including diseased cells, stem cell derived cells, immortalized cells, biosensor cells, • dentify intracellular transduction cascades for G-protein coupled receptors and I transfection of difficult cells and cell expansion services. We also offer improved prediction kinases. from cell models, including contextual cell-based assays for toxicity and mechanism-of-action • Accelerate high-content screening using primary cells. assessment. We make reagent production easier for our customers with our Cells on Demand™ Services and putting the assays you already use into biologically relevant primary cells. • ncorporate computational models to study the effects of drugs on intracellular I networks. For further information please visit: www.lonza.com • se 3D cell assays for more relevant testing of the effects of drugs on organs, U Scottish Biomedical offers a full range of biology services from including the liver, heart and brain cells. protein expression and expression optimisation through to in • arness human embryonic, adult and induced pluripotent stem cells for drug H vitro screening, cell based assays and in vivo models. Our team discovery, development and toxicity testing. will design and validate unique assays to suit your specific needs, using primary cells or custom made cell lines of your choice. As experts in cell signaling, we specialise in I look forward to meeting you at the conference cell-based and in vitro assays to determine compound effects on targets such as PDEs, Best regards HDACs, ion channels, GPCRs, and kinases. For further information please visit: www.scottish-biomedical.com Hamamatsu Photonics is a world-leading manufacturer of P H O T O N I S optoelectronic components and systems and provides solutions for O U R B U S I N E S S Nicholas Stone a wide variety of applications including imaging devices for Life Sciences. We will introduce our camera-based dispensing and imaging range, the FDSS Head of Conferences series for fluorescence and luminescence. The FDSS7000 is a fully modular HTS system and the FDSSµCELL is specifically designed for small throughput and assay development. Based on our famous camera range the FDSS series provides high sensitivity and fast readout times of a few minutes. Who should attend? For further information please visit: www.hamamatsu.co.uk Presidents, Chief Executive Officers, VPs, Global Heads, Chief Scientific Merck Millipore is the Life Science division of Merck KGaA of Germany Officers, Directors, Principal Scientists, Franchise Heads and Investigators in: and offers a broad range of innovative, performance products, services and business relationships that enable our customers’ success in • High-Throughput/High-Content Screening Operations research, development and production of biotech and pharmaceutical • Bioanalytical Development drug therapies. Through dedicated collaboration on new scientific and • Compound Profiling engineering insights, and as one of the top three R&D investors in the Life Science Tools • Drug Discovery/Validation industry, Merck Millipore serves as a strategic partner to customers and helps advance the • Cellular Imaging promise of life science. Headquartered in Billerica, Massachusetts, the division has around • Lead Generation 10,000 employees, operations in 64 countries and pro forma 2009 revenues of $2.9 billion. • In Vitro Sciences Merck Millipore operates as EMD Millipore in the U.S. and Canada. • ADMET For further information please visit: www.merckmillipore.com • Pre-clinical Development • Medicinal Chemistry Media Partners: • Toxicology PharmiWeb.com is the leading industry-sponsored portal for • Stem Cell Technologies & Platforms the pharmaceutical sector. Supported by most of the leading • Pharmacovigilance and Safety Testing pharmaceutical corporations, PharmiWeb.com provides dynamic real-time news, features, • Chemistry and Bioapplications events listings and international jobs to industry professionals across Europe and the US. • GPCR/Kinases/Molecular Pharmacology • External/Contract Research For further information please email: firstname.lastname@example.org • Pharmacokinetics/Pharmacodynamics BIOTECHNOLOGY EUROPE is owned by BIOTECHNOLOGY WORLD. • Cellular Research and Development It is based and located in Warsaw, Poland. Biotechnology World • Business Development was founded in 2007 to provide the world’s biotech and pharma • Investment and Venture Capital information and market to make it universally accessible and useful for scientific and business processes. Its first step to fulfilling that mission was building the BIOTECHNOLOGY EUROPE platform that will allow a quick spread of information in different channels. BIOTECHNOLOGY EUROPE offers companies completed internet public relations, publication and marketing solutions. One of the mains goals of BIOTECHNOLOGY EUROPE is to integrate the Biotech and Pharma Sector in Europe to global biotechnology, pharmaceutical and life science activities.Sponsorship and exhibition opportunities For further information please visit: www.biotechnology-europe.comThis event offers a unique opportunity to meet and do business with some of the key Future Pharmaceuticals has forged powerful relationships with Driving the Industry Forward | www.futurepharmaus.complayers in the pharmaceutical and biotech industries. If you have a service or product to key industry leaders to provide a platform for successful brand promote, you can do so at this event by: recognition, and for senior decision-makers to have the means • Hosting a networking drinks reception to procure and plan implementation strategies based on the topics covered. Positioned to be an authoritative resource within top pharma companies as well as small, specialty, and • Taking an exhibition space at the conference biotech, Future Pharmaceuticals magazine is geared to create a deep penetration into a • Advertising in the delegate documentation pack highly targeted and responsive audience, bridging the gap between the industries’ top issues • Providing branded bags, pens, gifts, etc. and the solutions top-tier vendors can provide.If you would like more information on the range of sponsorship or exhibition possibilities For further information please visit: www.futurepharmaus.comfor visiongains 2nd Annual Cell-Based Assays Conference, please contact us: InPharm is the online platform for exclusive pharmaceutical news, comment, contracts, services, jobs and events and is Damian Gorman, +44 (0)20 7549 9934 home to InPharmjobs.com, Pharmafile and Pharmafocus.email@example.com For further information please visit: www.In-Pharm.com
Pre-Conference Interactive Workshop 2nd Annual Cell-Based Assays Tuesday 11th October 2011Industrial application of pluripotent stem cells and their derivatives High-content screening as a valuable tool for drug discovery and toxicity testingLed by: Mikael Englund, Senior Scientist, Site Manager, Cellartis Panellists: Petter Björquist, Senior Principal Scientist, Project Manager, Cellartis Daniella Steel, Senior Scientist, Project Leader, Cellartis Anders Aspegren, Senior Scientist, Production Manager, Cellartis Paul Andrews, Senior Scientist, Drug Discovery Unit, University of DundeeTimings: About your workshop leaders:09:30 Registration and coffee An introduction to pluripotent stem cells, Industrialisation of stem cells Introduction to high-content screening and assay design Screen execution and follow-up Mikael Englund12:40 Lunch13:40 Case studies, lessons learnt, Stems cells in predictive toxicology Mikael Englund has been part of Cellartis’ stem cell team since 2001 Stem cell derivatives in screening and moved to develop UK operations in Dundee 2007. The UK site15:00 Panel discussion Q1: How predictive are stem cell based discovery systems? Is there manufactures large scale volumes of human ESCs and develops advanced added value above existing systems? culture technology and engineering tools, e.g. for drug screening and Q2: Are stem cell based platforms compatible with the time lines and automation systems required in an industrial environment? other applications. The facility also partners with Novo Nordisk to find a Q3: What is the future for stem cell based discovery systems in the drug cure for diabetes. discovery pipeline Mikael’s responsibilities at Cellartis have ranged from fundamentalAbout the workshop hESC research to industrial production of hESCs for screening. He has aDemands for better models of human disease and more predictive screening large network in the field and more than nine years experience of theassays to reduce late stage drug attrition, have promoted a growing interest inapplying pluripotent stem cells (PSCs) and their derivatives at various points in challenges of commercial stem cell business. He has a M.Sc. in molecularthe drug discovery pipeline. Furthermore, the use of PSCs in identifying small biology and a Ph.D. in Medicine.molecules active in directing cellular reprogramming or differentiation, is aparticularly promising tool for the regenerative medicine field.This workshop will review recent advances in the field including issuessurrounding cell quality, supply and banking, assay development and the screening Daniella Steelprocess. It will evaluate the benefits of using 3D models, as well as address theefficacy of PSC-based models for assessing human developmental, cardiac and Daniella Steel is a senior scientist at Cellartis, within R&D at thehepatic toxicity. Case studies of different compound screening campaigns usingPSCs and their derivatives, will permit exploration of the field in detail. Gothenburg site, Sweden. Daniella is involved in the differentiationLessons learned: and application of stem cell-derived cardiomyocytes. Her interests• Examples of scaled up pluripotent stem cell culture for industrial applications include the innovation and commercialision of stem cell based tools for• Assay design considerations drug discovery and safety assessment. Through developing industrial• Examination of screening platforms and strategies applications, Daniella has worked closely with pharmaceutical industry• A review of stem cell derivatives for screening and biosensor technology providers. Daniella earned her Ph.D. in electrophysiology from the faculty of Medicine, Imperial College, London. Her background in establishing cellular diseaseAbout Cellartis: models continued with international experience at McGill University,Cellartis AB is a Swedish/British biotechnology company focused on pluripotent stem cellsand technology for drug discovery research, toxicity testing and regenerative medicine. Since Canada, and at Chalmers University of Technology, Sweden.2001, Cellartis has worked globally with industry and academia, platform providers andend users, to develop the next generation of advanced stem cell products and technologies.The company leverages deep experience in stem cell handling, scale up and differentiationinto mature and functional human cells. The company was first in the world to bring to the Paul Andrewsmarket human embryonic stem (hES) cell-derived hepatocytes and cardiomyocytes for use asdrug discovery tools today. I obtained a Biochemistry B.Sc and Ph.D in Molecular Biology from theAbout The Drug Discovery Unit, University of Dundee University of Sheffield. In 1993 I moved to the University of Dundee, toThe Drug Discovery Unit (DDU) based in the College of Life Sciences at the University of pursue my interest in signalling, first using budding yeast and, later, usingDundee, is a unique example of academic drug discovery. The remit of the DDU is to tacklehigh-risk and/or novel targets in areas of unmet medical need. The DDU has all of the human cells. Since 2007 I have been leading the Stem Cell Programmecapabilities required for early phase drug discovery: from assay development, HTS and cellbiology, to medicinal chemistry, structural biology, computational chemistry and ADME/ in the Drug Discovery Unit at Dundee. I established the high-contentDMPK. All of these capabilities operate under one management structure to ensure an screening capabilities and headed several successful screening campaignsintegrated approach and rapid progress.Currently the team is about 30 people and includes substantial experience from the using human ES cells or their derivatives. My current interests lie inpharmaceutical/ biotech sector. Since 2007 the DDU has collaborated with Cellartis using hES targeting signalling pathways using small molecules to: engineer cellcells and their derivatives in high-throughput screening campaigns, to find small moleculesable to manipulate stem cell fate. fate; induce nuclear reprogramming and target cancer stem cells.
Day 1 2nd Annual Cell-Based Assays Wednesday 12th October 2011 09:00 Registration and refreshments 14:40 Label-free methods- where are we and what are 09:30 Opening address from the Chair the prospects for the future? PANEL DISCUSSION Rachel Russell D espite their increasing importance, when will it be commercially viable to Director, Primary Pharmacology Group integrate non-invasive methods into HT screening? Can relevant quantities Pfizer of primary cells be secured to enable this? The utility of label-free methods to reduce attrition rates and the conditions necessary to obtain real-time, 09:40 Impact of new technologies for cellular screening quantitative measurements will be thoroughly assessed. Join this lively along the drug value chain session and email your questions to: firstname.lastname@example.org. • Primary, stem cell, 3D and label-free screens employing cellular assays Chair: Magalie Rocheville, Investigator, GlaxoSmithKline • Ion channel screening • Atomic force microscopy in drug discovery and development Mark Slack, Group Leader, Cellular Assays, Evotec Mark Slack, Group Leader, Cellular Assays, Evotec Miroslav Cik, Research Fellow, Janssen Pharmaceutica Clemens Möller, Professor of Biophysics, (Johnson & Johnson) Albstadt-Sigmaringen University Molly Stevens, Professor of Biomedical Materials and Regenerative Medicine, Imperial College London 10:20 A novel, rapid and automated method for creating 3D tissue models to study complex cell behaviour 15:20 Development of cell-based methodologies relevant • What type of information can 3D tissue models provide? • What is preventing widespread adoption of 3D tissue models? to ion channel drug discovery • The route to scalable and tuneable 3D tissue models • irect and indirect measurement of ligand- and ion-gated channels in D Rosemary Drake recombinant lines Chief Scientific Officer • Electrophysiology using stem cell derived neurons TAP Biosystems • Native tissue electrophysiology Fiona Harris 11:00 Morning refreshments Senior Scientist Scottish Biomedical 11:20 Unlocking the potential of 3D cell culture with Alvetex technology 15:40 Afternoon refreshments • 2D vs 3D cell culture • Development of unique scaffold 16:00 Development of a multiplexed gene expression • Optimizing routine 3D cell culture assay in primary neurons Stefan Przyborski • uantification of compound-induced changes to expression of pain-related genes Q Founder and Chief Scientific Officer • hallenges of using native neuronal cells as reagents for primary screening C Reinnervate • pplication of the assay for compound profiling and new target identification A Darren Cawkill 11:40 Application of a 3D tumour cell culture model to Associate Director, Primary Pharmacology Group compound screening Pfizer • Three dimensional growth assay and image analysis • Plate-based, label-free, high-content analysis evaluation 16:40 The FDSS series: a versatile platform for HTS and • Screening validation and pre-clinical results assay development Miroslav Cik • Primary culture and cell line assays in fluorescence and luminescence Research Fellow • Whole dispensing and imaging screening systems for cell-based assays Janssen Pharmaceutica (Johnson & Johnson) • Applications: new epilepsy model and luminescence multiplexing Christelle Catone 12:20 Integration of label-free detection methods in FDSS Application Scientist, Systems Division GPCR drug discovery Hamamatsu Photonics • Comparison of impedance and optical read-outs • Recombinant cells vs endogenous GPCR signalling 17:00 Executable cell biology • Native receptor activity in disease-relevant cells • Mathematical versus computational models Magdalena Birker-Robaczewska • Models for executable biology Senior Lab Head, Cardiovascular & Fibrosis Biology • Challenges for testing dynamics in complex systems Actelion Pharmaceuticals Jasmin Fisher Researcher, Executable Biology 13:00 Networking lunch Microsoft Research Cambridge 14:00 Rapid non-invasive analysis of live cells 17:40 Closing remarks from the Chair • Global fingerprinting of cells with live cell Raman spectroscopy • Applications in toxicology • Applications in cell differentiation 17:50 Networking drinks Molly Stevens Take your discussions further and build new Professor of Biomedical Materials and Regenerative Medicine relationships in a relaxed and informal setting Imperial College London Due to unforeseen circumstances the programme may change and visiongain reserves the right to alter the venue and/or speakers c Copyright visiongain Ltd, 2011
Day 2 2nd Annual Cell-Based Assays Thursday 13th October 201109:00 Registration and refreshments 14:00 Enabling technology to enhance cell differentiation and function in vitro • ell differentiation in 3D culture using primary MSCs and pluripotent stem cells C09:30 Opening address from the Chairs • evelopment of small molecules to control reproducible human neural D Joanne Bowes differentiation in vitro Principal Scientist/Team Leader, Safety and Secondary Pharmacology • se of small molecules to differentiate a 3D skin equivalent model with U AstraZeneca human keratinocytes Stefan Przyborski09:40 Early toxicity testing: prediction and Founder and Chief Scientific Officer tissue-specific models Reinnervate • Early toxicity testing paradigms • Cellular models for toxicity testing, focusing on the liver, lung and heart 14:20 Predicting idiopathic cardiotoxicity with 3D heart • Prediction models using global expression profiling tissues: combining rodent and human models Stefan Otto Mueller • ardiac contractility response to a panel of cardio-toxic drugs with iPSC C Director, Early, Genetic and Molecular Toxicology and ESC based 3D engineered heart tissues Merck Serono • Cost-effective and the most predictive screening approach • dentifying idiopathic cardiotoxicity mechanisms for searching preventive I10:20 Protein-fragment complementation assays and strategies compound profiling Tetsuro Wakatsuki Anthony Pitt Co-Founder and Chief Scientific Officer Technical Director Assays and Technology Development InvivoSciences Lonza 14:50 Generating metabolically active hepatocytes from10:40 Key considerations in the development of stem pluripotent stem cells • tem cells offer an unlimited source of hepaotcytes for human drug screening S cell assays in predictive toxicology • Stem cell derived hepatocytes exhibit phenotypic instability in culture • The need for improved drug screening models to predict risk for man • e have identified a novel support which stabilises hepatocellular phenotype W • rerequisites for successful development of stem cells assays in toxicity testing P • C4SM Predictive Toxicology Consortium: challenges and S David C. Hay future opportunities Principal Investigator, MRC Centre for Regenerative Medicine University of Edinburgh Frank W. Bonner Chief Executive Stem Cells for Safer Medicines 15:30 Afternoon refreshments11:20 Morning refreshments 15:50 Opportunities and challenges for human stem cells11:40 Therapeutic and research potential of human stem in drug screening ill hES and hPS/iPS-derived specialised cells better reflect human variation to W PANEL DISCUSSION cells (hSCs) – the GE Healthcare perspective toxic agents and match biological possibilities with end-user constraints? Can • How hSCs will revolutionise medical care through regenerative strategies idiopathic and ethnic libraries aid patient stratification, or will cellular models • ow hSCs will improve quality, price and accessibility of new pharmaceuticals H remain oversimplifications? What new insights will organogenesis and disease • aximising hSC use in big pharma drug discovery and safety assessment studies M models provide? Answers to these and other matters, including regulatory Stephen Minger requirements and up-scaling for robust industrial production will be addressed. Global Head of R&D, Cellular Technologies Please email your questions for the panel to: email@example.com. GE Healthcare Chair: Julie Holder, Preclinical Director, Stem Cell DPU, GlaxoSmithKline Stephen Minger, Global Head of R&D, Cellular Technologies, GE Healthcare12:20 Human pluripotent stem cells (hPSCs) and their use Petter Björquist, Senior Principal Scientist, Project Manager, Cellartis in drug discovery and cellular assays Frank W. Bonner, Chief Executive, Stem Cells for Safer Medicines • Importance of scaleable systems for industrial stem cell production David C. Hay, Principal Investigator, MRC Centre for Regenerative • ellular toxicity testing using hPSC derived cardiomyocytes and hepatocytes C Medicine, University of Edinburgh • hPSC technologies compared to traditional in vitro and in vivo assays Petter Björquist Senior Principal Scientist, Project Manager Cellartis 16:30 Chair’s closing remarks13:00 Networking lunch 16:40 End of conference
Registration Form 2nd Annual Cell-Based Assays 11th - 13th October 2011, London, UK Angel Conf. code PP Pentonville Road 2nd Annual CiStandard Prices ty Cell-Based Assays Ro adConference and workshop Fee: £1699 VAT: £339.80 Total: £2038.80Conference only Fee: £1299 VAT: £259.80 Total: £1558.80 11th - 13th October 2011 Old StreetWorkshop only Fee: £599 VAT: £119.80 Total: £718.80 Location: Visiongain Conference Centre Old StreetNumber of bookings: Total cost: Address: 230 City Road City Road LondonPromotional Literature Distribution EC1V 2TTDistribution of your company’s promotional literature to all conference attendees UK Fee: £999 VAT: £199.80 Total: £1198.80 How to bookDetails Email: Piyush.firstname.lastname@example.org Forename: Surname: Web: http://www.visiongain.com/cell-based-assays UK Office:Job Title: Company: Tel: +44 (0) 20 7549 9961 Fax: +44(0) 20 7549 9932 Main Switchboard Number: Visiongain Ltd 230 City Road LondonAddress: EC1V 2QY UK General information Venue: Venue: Directions: Visiongain Conference Centre 230 City Road, London, EC1V 2TT. United Country: Postcode: Kingdom. Closest tube station is Old Street (Northern Line). Accommodation: Thistle City Barbican, Central Street, Clerkenwell, London, EC1V 8DS, Phone: 0871 376 Phone: Fax: 9004 / +44 845 305 8304, Fax: 0871 376 9104 / +44 845 305 8343 http://www.thistle.com/en/hotels/united_kingdom/london/thistle_city_barbican/index.html Travelodge London City Road Hotel, 7-12 City Road, London, EC1Y 1AE, Tel: 0871 984 6333, Fax: 0207 Email: 628 2503, http://www.travelodge.co.uk/search_and_book/hotel_overview.php?hotel_id=340 Payment terms: Visiongain require the full amount to be paid before the conference. Visiongain Signature: Ltd may refuse entry to delegates who have not paid their invoice in full. A credit card guarantee may be requested if payment has not been received in full before the event. Visiongain Ltd reserves the I confirm that I have read and agree to the terms and conditions of booking right to charge interest on unpaid invoices. Substitutions/name changes or cancellations: There is a 50% liability on all bookings once Methods of payment made, whether by post, fax, email or web. There is a no refund policy for cancellations received on or after one month before the start of the event. Should you decide to cancel after this date, the full invoice Payment must be made in sterling must be paid. Conference notes will then be sent to you. Unfortunately, we are unable to transfer places between conferences. However, if you cannot attend the conference, you may make a substitution/name By Mail: Complete and return your signed registration form together with your cheque payable change at any time, as long as we are informed in writing by email, fax or post. Name changes and to Visiongain Ltd and send to: visiongain Ltd, BSG House, 226-236 City Road, London, EC1V 2QY, UK substitutions must be from the same company or organisation and are not transferable between countries. Please note that discounted delegates places at a visiongain event are non refundable.By Fax: Complete and fax your signed registration form with your credit card details Invoice alterations: There will be an administration charge of £50 for any changes to an invoice, to +44 (0) 20 7549 9932 excluding substitutions/name changes, requested by the customer. This will be charged to the customer by credit card prior to the changes being made.By Phone: Call us on +44 (0) 20 7336 6100 with your credit card details Indemnity: Visiongain Ltd reserves the right to make alterations to the conference/executive By Credit Card: Fill in your card details below and fax back to +44 (0) 20 7549 9932 briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled due to unforeseen events beyond the control of visiongain Ltd. If such a situation arises, we will try By Bank Transfer: to reschedule the event. However, visiongain Ltd cannot be held responsible for any cost, damage or expenses, which may be incurred by the customer as a consequence of the event being postponed or Visiongain Ltd A/C: visiongain Ltd cancelled. We therefore strongly advise all our conference clients to take out insurance to cover the Barclays Bank Sort Code: 20-71-64 cost of the registration, travel and expenses.Piccadilly Branch Account No: 6038 7118 Data Protection: Visiongain Ltd gathers and manages data in accordance with the Data 48 Regent Street Swift Code: BARC GB22 Protection Act 1988. Your personal information contained in this form may be used to update you on visiongain Ltd products and services via post, telephone, fax or email, unless you state otherwise. We London, W1B 5RA IBAN: GB80 BARC 20716460387118 may also share your data with external companies offering complementary products or services. If you wish for your details to be amended, suppressed or not passed on to any external third party, please Please debit my credit card: send your request to the Database Manager, visiongain Ltd, BSG House, 226-236 City Road, London, Access MasterCard Visa American Express EC1V 2QY. Alternatively, you can visit our website at www.visiongain.com and amend your details. Please allow approximately 30 days for your removal or update request to be applied to our database. Following your removal or update request, you may receive additional pieces of communication from visiongain Ltd during the transitional period, whilst the changes are coming into effect.Card number: Fee: The conference fee includes lunch, refreshments and conference papers provided on the day. This fee does not include travel, hotel accommodation, transfers or insurance, (which we strongly recommend you obtain).Expiry Date: VAT: VAT will be charged at the local rate on each conference. Delegates may be able to recover VAT incurred by contacting Eurocash Corporation plc +44 (0) 1273 325000, email@example.com. Security number (last 3 digits on back of credit card): Eurocash specialise in recovering cross-border VAT. How we will contact you: Visiongain Ltd’s preferred method of communication is by email and Signature: phone. Please ensure that you complete the registration form in full so that we can contact you. Unable to attendCardholder’s name: Obviously nothing compares to being there but you need not miss out. Simply tick the box and send with your payment. You will receive speaker talks in PDFs two weeks after the event.News updates Yes, please send me speaker talks Price£550 VAT:£110 Total:£660Please tick if you do not want to receive email news updates in the future www.visiongain.com/cell-based-assays